US/UK/Canada

Share

Contacts

  • Pål Ryfors

    CEO


    Karlavägen 60, 114 49 Stockholm
    0709623669
    http://www.episurf.com
    • Pick a time period -
    Tags ( Active)

    Long-term Episealer® clinical results to be presented at international congress

    Episurf Medical (Nasdaq: EPIS B) today announces that the abstract “SURVIVORSHIP AND CLINICAL OUTCOMES OF A NOVEL PERSONALIZED METAL IMPLANT FOR THE TREATMENT OF CARTILAGE LESIONS OF THE KNEE”, by Dr Francesca de Caro has been accepted for presentation at the ISAKOS (International Society of Arthroscopy, Knee Surgery and Orthopaedic Sports Medicine) congress in Munich, Germany, on June 8-11, 2025. The abstract with up to 10 years’ follow-up reports on high implant survival and good clinical outcomes for 34 patients who were treated with Episurf Medical’s individualised implant Episealer®

    Episurf Medical to present at Redeye Theme Event: Commercialization in Life Science

    Episurf Medical (Nasdaq: EPIS B) will attend Redeye Theme Event: Commercialization in Life Science which is held on March 20th, 2025. The event is arranged by Redeye and Episurf will be represented by its CEO Pål Ryfors. The format will be a 12-minute pitch followed by an 8-minute Q&A.The presentation will be streamed live at 10:10 CET at: https://www.redeye.se/events/1073684/redeye-theme-commercialization-in-life-science-2 and will also be made available afterwards on our website www.episurf.com.Location: Redeye, Mäster Samuelsgatan 42, Stockholm.

    Episurf Medical AB announces outcome of exercise of warrants of series TO13 B

    THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, THE UNITED KINGDOM, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, ISRAEL, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, OR ANY OTHER JURISDICTION WHERE SUCH DISTRIBUTION WOULD REQUIRE ADDITIONAL PROSPECTUS, REGISTRATION OR OTHER MEASURES IN ADDITION TO THOSE REQUIRED BY SWEDISH LAW, IS PROHIBITED, OR OTHERWISE IS UNLAWFUL OR CANNOT BE MADE WITHOUT THE APPLICATION OF AN EXEMPTION FROM SUCH ACTION. REFER TO THE SECTION "IMPORTANT

    Year-End Report 1 January - 31 December 2024

    · Significant result and cash flow improvements · Distribution agreement with Joint Operations for several European markets · First sales through the Johnson & Johnson distributor network “We hereby conclude the year 2024, a year in which we have made great progress. We have delivered on a significant part of our cost savings program. In the fourth quarter of 2024, we improved operating cash flow by SEK 7.6m to SEK -12.9m, a development I am very happy about. During 2024, we delivered on a substantial part of our cost reduction program, and we are now seeing a clearly improved

    US VAC permissions granted for Episurf Medical

    Episurf Medical (Nasdaq: EPIS B) today announces several recent permissions granted from health systems’ Value Analysis Committees (VACs) within the United States. While typical sales cycles begin with interest from an orthopaedic surgeon, review and access to begin doing surgeries must almost always first be granted by individual VACs. Recently, among others, the company has received approval to initiate surgeries within facilities at: · Vail Health System (affiliated with the Steadman Clinic) – Vail, Colorado · The Hospital for Special Surgery – New York, New York · Dartmouth

    Episurf Medical to present at Redeye Technology & Life Science Day on December 3rd, 2024

    Episurf Medical (Nasdaq: EPIS B) will attend Redeye Technology & Life Science Day which is held on December 3rd, 2024. The event is arranged by Redeye and Episurf will be represented by its CEO Pål Ryfors. The format will be a 2-minute pitch followed by a 16-minute Q&A session. The presentation will be streamed live at 09:00 CET at: https://www.redeye.se/events/1038747/redeye-technology-life-science-day and will also be made available afterwards on our website www.episurf.com. Location: Sergelkonferensen, Mäster Samuelsgatan 42 (Sveavägen 9), Stockholm.

    Episurf Medical to present at Redeye Medtech & Diagnostics Event on November 13th, 2024

    Episurf Medical (Nasdaq: EPIS B) will attend Redeye Medtech & Diagnostics Event which is held on November 13th, 2024. The event is arranged by Redeye and the company will be represented by its CEO Pål Ryfors. The format will be a 12-minute presentation followed by an 8-minute Q&A Session. The presentation will be streamed live at 09:50 CET at https://www.redeye.se/events/1016182/redeye-theme-medtech-diagnostics-3 and will also be made available afterwards on our website www.episurf.com. If you would like to attend the event in person, you can register at https://crm.redeye.se/events/

    Interim Report 1 January - 30 September 2024

    · Improvement of financial result through lower cost base and increased revenues · Focus towards expansion of US sales force · Continued progress of 510(k)-process for great toe implant “I am pleased to present a quarterly report in which we seriously demonstrate that our measures positively impact the income statement. In the third quarter, we improved our result by SEK 4.9m compared to the corresponding quarter last year, and we now see that our cost-saving initiatives are yielding results. With increased revenues, we have good opportunities to continue to step into the

    Niles Noblitt, through Sacajo Investments LLC, makes investment in Episurf through an arrangement with CEO Pål Ryfors

    In order to facilitate settlement of an acquisition of 9,526,170 Class B shares in Episurf Medical AB (publ) (“Episurf” or the “Company”) by Sacajo Investments LLC (“Sacajo”), a trust with the Company’s Senior Advisor Niles Noblitt as first member, Sacajo and Pål Ryfors, CEO of Episurf, have agreed that Pål Ryfors shall hold the shares during an interim period. Consequently, Pål Ryfors will acquire 9,526,170 Class B shares in Episurf from Sacajo for a purchase price of SEK 2,286,280.80, corresponding to SEK 0.24 per share. Payment for the shares is made by Pål Ryfors issuing a promissory

    Episurf Medical: Update on 510(k) application for big toe implant

    Episurf Medical (Nasdaq: EPIS B) today provides an update on the company's 510(k) application to the US FDA, for market clearance of the company's implant for treatment of osteoarthritis in the so-called 1st MTP joint in the big toe. During this process, the company has exchanged information with the FDA, and this process will continue shortly. "We are pleased to have come this far in the process. We have in-depth experience of interacting with the FDA, and we know that it is difficult to forecast these processes accurately, but we certainly feel that we are moving forward. We will not

    Episurf Medical to present at Pareto Securities Healthcare Conference on September 19, 2024

    Episurf Medical (Nasdaq: EPIS B) to present at Pareto Securities Healthcare Conference on September 19, 2024. The event is arranged by Pareto and the company will be represented by its CEO Pål Ryfors. Time: 11:05-11:25 CESTFormat: 20 minutes including Q&ALocation: Studio 8, Downtown Camper, Drottninggatan 28, 111 51 Stockholm The presentation slides will be made available afterwards on our website www.episurf.com.

    Episurf Medical to present at Life Sciencedagen on March 6, 2024

    Episurf Medical (Nasdaq: EPIS B) will attend Life Sciencedagen which is held on March 6, 2024. The company will be represented by its CEO Pål Ryfors. The presentation will be streamed live at 14:45 CET at www.lifesciencedagen.se  and will also be made available afterwards on our website www.episurf.com. The event takes place at Wallenberg Conference Center, Sahlgrenska Academy, at Medicinareberget in Gothenburg.

    Episurf Medical to present at Redeye Life Science Day on November 23rd, 2023

    Episurf Medical (Nasdaq: EPIS B) will attend Redeye Life Science Day which is held on November 23rd, 2023. The event is arranged by Redeye and the company will be represented by its CEO Pål Ryfors. The format will be a 2-minute Elevator Pitch followed by a 20-minute InFocus Q&A Session. The presentation will be streamed live at 15:40 CET at https://www.redeye.se/events/915984/redeye-life-science-day-2023 and will also be made available afterwards on our website www.episurf.com.

    Episealer® presentations at several clinical congresses

    Episurf Medical (Nasdaq: EPIS B) today announces that the company’s knee and ankle technologies, Episealer® Knee and Talus, recently have been presented at several clinical congresses, as part of the scientific program or through surgeon-led initiatives. At the 29[th] International Congress of SLAOT (Sociedad Latinoamericana de Ortopedia y Traumatología) in San José, Costa Rica (September 20-22), Dr Christian Kothny gave a presentation on the Episealer® implant technologies, focusing on clinical indications, surgical techniques, and clinical results. At the XL Orthopedic Days, organised

    Scientific article on Episealer® Talus surgical technique published in Foot & Ankle Clinics

    Episurf Medical (Nasdaq: EPIS B) today announces that an article on the surgical technique for Episurf Medical’s implant system for treatment for osteochondral defects in the ankle joint, Episealer® Talus, has been published in the scientific journal Foot & Ankle Clinics. The publication, with the title “Personalized Resurfacing for Osteochondral Lesions of the Talus”, by F. G.  Usuelli, MD, B. Efrima, MD and Prof. N. van Dijk, covers areas such as the etiology of typical ankle lesions and alternative treatment methodologies, in addition to providing a detailed review of the surgical

    Prospective Episealer® Talus clinical study fully recruited

    Episurf Medical (Nasdaq: EPIS B) today announces that all patients have been recruited to a prospective clinical study on the Episealer Talus® implant, led by Prof. Stefano Zaffagnini, from the Rizzoli Orthopaedic Institute in Bologna, Italy, supported by Dr Massimiliano Mosca and Prof. Niek van Dijk. The study will follow 20 patients who received an Episealer Talus® implant as treatment for osteochondral defects in their ankle joint. Episealer® Talus is Episurf Medical’s CE marked implant technology, intended for the treatment of ankle lesions.  “Our technology for ankle lesions is

    Episurf Medical to present at Pareto Securities Healthcare Conference on September 14, 2023

    Episurf Medical (Nasdaq: EPIS B) will present at Pareto Securities Healthcare Conference on September 14, 2023. The event is arranged by Pareto and the company will be represented by its CEO Pål Ryfors. Time: 16:15-16:35 CESTFormat: 20 minutes including Q&ALocation: Hotel At Six, Brunkebergstorg 6, Stockholm (Studio 8) The presentation slides will be made available afterwards on our website www.episurf.com.

    Results from the use of Episealer® accepted for publication in scientific journal

    Episurf Medical (Nasdaq: EPIS B) today announces that results from a follow-up study on the Episealer® knee implant have been accepted for publication (peer-reviewed) in the Journal of Experimental Orthopaedics. The article, with the title “2-year results of middle-aged patients with two-compartment cartilage lesions in one knee treated with two patient specific metal implants”, by Daniel Aaron den Toom, Markus Rieke, Allaeldin Elbadawi and Clemens Kösters, focuses on the clinical outcome from follow-up of patients treated with two implants in the same knee. The patients have been followed-

    Episurf Medical: Strategy update to take the next commercial steps and improve financial results

    Episurf Medical (Nasdaq: EPIS B) today announces that the company is implementing a strategic focus that brings an increased focus on the US market, as well as a transition to a distributor model for other key markets. The company sees great opportunities for continued commercialization within selected market segments. The strategic focus means: · Operational measures to significantly improve the company's financial position and running costs. · Accelerate the path towards, and increase transparency for, operational profitability. · Increased focus on distributor sales and

    Correction of previously communicated press release

    Press release 30 June 2023 14:50 CEST Correction of previously communicated press release Episurf Medical AB (publ) ("Episurf") announces correction in relation to the press release "RECORD DAY FOR FREE WARRANTS OF SERIES TO4B AS WELL AS INFORMATION ABOUT PERIOD FOR EXERCISING WARRANTS OF SERIES TO4B" published on May 23, 2018. The press release incorrectly stated that subscription of shares through the exercise of warrants of series TO4B will be possible during the period Thursday, November 9, 2023 until Thursday, November 23, 2023. According to the terms and conditions of the

    Episealer® Patellofemoral System available in United Arab Emirates

    Episurf Medical (NASDAQ: EPIS B) today announces that the Ministry of Health & Prevention in the United Arab Emirates has issued a classification letter for the company’s implant technology Episealer® Patellofemoral System, allowing sales in the United Arab Emirates market. The classification follows after a review process. “As soon as we got the Episealer® Patellofemoral System clearance in the United States, we started the regulatory work of bringing the technology to other markets. The United Arab Emirates is now the second country that cleared the product for sale, and we are

    Episurf Medical to present at Redeye Growth Day today, June 1st, 2023

    Episurf Medical (Nasdaq: EPIS B) will present at Redeye Growth Day today, June 1st, 2023. The event is arranged by Redeye and will be streamed live. The company will be represented by its CEO Pål Ryfors. Time: 09:40 CESTFormat: 2 minutes live pitch followed by 18 minutes of Q&A Link to the livestream Q&A (Stream 2):  https://www.redeye.se/events/871323/redeye-growth-day?tab=companypresentations   Link to the accompanying pre-recorded presentation: https://www.redeye.se/video/company-prerecorded-presentation/912672/episurf-medical-3 The presentation will also be made available

    Episurf Medical to present at Innovative Orthopedics hosted by Redeye on March 21st, 2023

    Episurf Medical (Nasdaq: EPIS B) will present at Innovative Orthopedics on March 21st, 2023. The event is arranged by Redeye and will be streamed live. The company will be represented by its CEO Pål Ryfors. Time: 11:20 CET Link to the livestream:  https://www.redeye.se/events/869691/innovative-orthopedic-1 The presentation will also be made available afterwards on our website www.episurf.com.

    There are no items matching the current filter
    There are no more items matching the current filter
    Back to top

    Subscribe

    Media